It explored the differences in efficacy in respective first-line treatments by genotyping them through the analysis of genome profiles to excavate the efficacy predictors of KRAS-mutant lung cancer and the prognostic value of different genotypes. The gene discussed is KRAS; the disease is lung carcinoma.